---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018025"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:23:20.445403+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oragenics partners with Avance Clinical for Phase II concussion trial of ONP-002 in Australia

## Summary
- Phase II trial to evaluate ONP-002 for mild traumatic brain injury (concussion) delivered intranasally.
- Phase I trial completed under Avance Clinical showed ONP-002 safe and well-tolerated.
- Avance Clinical, a CRO with 20+ years experience, will manage the trial in Australia.
- Oragenics President cites confident execution; CMO highlights Australia's head injury expertise.
- Worldwide annual concussions estimated at 69 million; post-concussion syndrome occurs in up to 20%.

## SEC filing metadata
- accession: 0001493152-24-018025
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315224018025/0001493152-24-018025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315224018025/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018025
- JSON: https://secwatch.observer/filing/0001493152-24-018025.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.